Coronavirus update: Biden administration increases vaccine doses to states; UK approves first human challenge trial
The U.S. federal government continues to increase state allotments of vaccine doses, even as winter weather slows down shipments and delays appointments, especially in Texas where power outages are ongoing.
States should expect a total of 13.5 million vaccines next week, an increase from 11 million this week, with additional shipments directly to pharmacies and federally qualified health centers.
Meanwhile, the country awaits Johnson & Johnson's (JNJ) vaccine authorization, which could come as early as the end of the month. But even with hopes pinned on the one-shot dose, White House COVID-19 Response Team coordinator Jeff Zients said Wednesday there won't be a sudden surge of vaccines available.
"There is not a big inventory," Zients said, adding that only a few million of the 100 million promised will be available by the end of June.
Zients said the administration is working with the company to determine how to ramp up production. Unlike the existing vaccines, J&J's is not based on a new technology and can likely use existing infrastructure.
Moderna (MRNA) announced Tuesday it is going to meet its production goals, with 100 million doses ready by the end of May, a month ahead of schedule, while doubling its monthly output to 40 million to 45 million doses per month beginning in April.
An additional 100 million doses will be produced by the end of July, instead of September, the company said in a statement. There has been some delay in the production process, based on an equipment issue with partner Catalent, that will be resolved in the short term and will not affect production targets, a Moderna spokesperson told Yahoo Finance.
The United States, meanwhile, has been ramping up vaccinations, with more than 55 million first and second doses administered, and more than 71 million have been distributed.
Federal Emergency Management Agency (FEMA) has begun to set up more vaccine sites and is staffing them with active military in a partnership with the Department of Defense. FEMA is designating small sites as those capable of completing 3,000 vaccinations per day, and larger sites handling double that amount. Large sites in New York and Texas have opened, and smaller ones in New Jersey and the U.S. Virgin Islands are planned, officials said Tuesday.
The White House is in conversations with Amazon (AMZN), according to Politico, and has been approached by other technology companies like Google (GOOG), Facebook (FB) and AirBnB (ABNB). The move marks a shift from recent Congressional attention on the tech sector's size and power.
Amazon, in particular, has been under fire for its treatment of warehouse workers throughout the pandemic. New York's Attorney General is suing the company for its alleged handling of worker safety issues and for retaliating when employees began to complain. The company preemptively sued to stop the lawsuit last week.
White House Press Secretary Jen Psaki said Tuesday during a briefing that the Biden administration is busy tackling response efforts since taking office last month.
"What (President Joe Biden) inherited was not enough supply, not enough vaccinators, not enough places for vaccinations to happen. Communities had been left to fend for themselves. And so, that's what he's been focused on and working on," Psaki said.
Variants and challenge trials
Even as vaccinations are on the rise, with more than 15% of the population inoculated, scientists are increasingly concerned as new variants emerge. The variant originally found in the U.K. (B.1.1.7) could be more deadly than the original strain, while the strains from South African (B.1.351) and Brazil (P.1) are showing more resistance to vaccines -- though they remain effective in blocking some level of infection.
A new strain, with similar mutations to the B.1.1.7 strain, has already been reported in several countries, including in the U.S.
Meanwhile, the U.K. approved the first human challenge trials, to begin through OpenOrphan (ORPH.L) Wednesday. The company anticipates it can play a role in helping second generation vaccines which could target virus variants through an expedited clinical trial process.
The company has already looked at nasal spray vaccine options, which is of interest for individuals who cannot receive injected doses for health reasons. Cogenix and Altimmune are already testing candidates and are in early clinical trial stages. Other companies have also identified oral candidate options, which are similarly in early phases.
More from Anjalee:
Telehealth's future depends on bridging the digital divide: Hospital CEO
What you need to know about at-home, over-the-counter COVID-19 tests
Biden COVID-19 adviser: Vaccine news is great, but we still have a ways to go
Read the latest financial and business news from Yahoo Finance.
Follow Yahoo Finance on Twitter, Facebook, Instagram, Flipboard, SmartNews, LinkedIn, YouTube.
Follow Anjalee on Twitter @AnjKhem.